Caribou Biosciences, Inc. - Common Stock (CRBU) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRBU on Nasdaq
Shares outstanding
92,189,700
Price per share
$1.59
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
37,024,074
Total reported value
$86,267,579
% of total 13F portfolios
0%
Share change
-3,615,978
Value change
-$6,935,234
Number of holders
115
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Caribou Biosciences, Inc. - Common Stock (CRBU) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Haurwitz Rachel E. 5% $4,008,603 4,716,003 Rachel E. Haurwitz 22 Apr 2025
VANGUARD GROUP INC 4.9% $3,843,727 4,522,032 The Vanguard Group 31 Mar 2025
BANK OF AMERICA CORP /DE/ 2.2% $1,658,405 1,951,065 BANK OF AMERICA CORP /DE/ 31 Dec 2024
BlackRock, Inc. 2% -69% $2,323,180 -$5,591,740 1,843,794 -71% BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 115 institutional investors reported holding 37,024,074 shares of Caribou Biosciences, Inc. - Common Stock (CRBU). This represents 40% of the company’s total 92,189,700 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Caribou Biosciences, Inc. - Common Stock (CRBU) together control 35% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 5.1% 4,690,431 0% 2.5% $10,928,704
VANGUARD GROUP INC 4.6% 4,226,926 +3.4% 0% $9,848,737
MILLENNIUM MANAGEMENT LLC 3.5% 3,216,535 +107% 0.01% $7,494,527
Kynam Capital Management, LP 3.3% 3,067,774 0% 0.53% $7,147,913
BlackRock, Inc. 1.6% 1,459,320 -23% 0% $3,400,215
Aberdeen Group plc 1.5% 1,388,905 +55% 0.01% $3,236,149
PFM Health Sciences, LP 1.5% 1,358,831 0% 0.27% $3,166,076
TWO SIGMA ADVISERS, LP 1.3% 1,227,400 -15% 0.01% $2,859,842
DIMENSIONAL FUND ADVISORS LP 1.3% 1,210,310 -7.4% 0% $2,819,859
BANK OF AMERICA CORP /DE/ 1.2% 1,074,442 +33% 0% $2,503,450
GEODE CAPITAL MANAGEMENT, LLC 1.1% 985,126 +0.43% 0% $2,296,349
TWO SIGMA INVESTMENTS, LP 0.85% 783,590 -16% 0% $1,825,765
RENAISSANCE TECHNOLOGIES LLC 0.85% 780,421 +47% 0% $1,818,381
Pale Fire Capital SE 0.84% 775,055 0% 0.2% $1,805,878
FMR LLC 0.79% 729,002 -0.06% 0% $1,698,574
MAVERICK CAPITAL LTD 0.71% 652,542 0% 0.02% $1,520,423
Cambridge Investment Research Advisors, Inc. 0.63% 582,387 -0.35% 0% $1,357,000
ROYAL BANK OF CANADA 0.62% 573,993 -4.2% 0% $1,337,000
Schonfeld Strategic Advisors LLC 0.61% 558,576 -75% 0.01% $1,301,480
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.61% 558,474 +5.5% 0% $1,301,244
JANE STREET GROUP, LLC 0.52% 479,438 -0.86% 0% $1,117,091
72 Investment Holdings, LLC 0.51% 474,067 0% 1.6% $1,104,576
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.48% 445,607 +68% 0% $1,038,264
XTX Topco Ltd 0.48% 441,541 +320% 0.05% $1,028,791
STATE STREET CORP 0.42% 386,263 +7.8% 0% $899,993

Institutional Holders of Caribou Biosciences, Inc. - Common Stock (CRBU) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,847,464 $2,937,467 +$17,013 $1.59 10
2025 Q3 37,024,074 $86,267,579 -$6,935,234 $2.33 115
2025 Q2 40,657,539 $51,233,181 -$11,182,668 $1.26 128
2025 Q1 50,124,474 $45,767,240 -$8,735,404 $0.91 127
2024 Q4 58,137,691 $92,442,260 +$1,344,135 $1.59 130
2024 Q3 52,230,454 $102,372,092 -$1,215,533 $1.96 124
2024 Q2 53,030,028 $86,964,603 -$69,072,988 $1.64 136
2024 Q1 66,748,618 $342,979,667 -$13,445,660 $5.14 149
2023 Q4 69,081,626 $395,824,161 -$5,845,565 $5.73 143
2023 Q3 70,779,287 $338,477,161 +$132,380,976 $4.78 126
2023 Q2 43,715,651 $185,309,815 -$6,639,016 $4.25 117
2023 Q1 44,984,864 $238,314,447 +$6,834,942 $5.31 126
2022 Q4 43,609,398 $273,911,420 -$3,252,217 $6.28 132
2022 Q3 43,252,045 $456,982,599 +$65,340,908 $10.55 114
2022 Q2 37,333,019 $202,972,596 +$14,914,954 $5.43 116
2022 Q1 34,952,083 $321,058,661 +$23,111,728 $9.18 103
2021 Q4 30,588,325 $457,556,044 -$490,819 $15.09 90
2021 Q3 29,587,281 $693,431,752 +$646,473,752 $23.87 86